A Single-centre, Randomised, Double-blind, Double-dummy, Placebo Controlled, 4-way Crossover Phase I Study to Investigate the Effect of 2 Single Doses (400 microg and 1200 microg) of Inhaled AZD3199 on QT/QTc Interval, Compared to Placebo, Using Moxifloxacin (Avelox) as a Positive Control, in Healthy Male Volunteers.

Trial Profile

A Single-centre, Randomised, Double-blind, Double-dummy, Placebo Controlled, 4-way Crossover Phase I Study to Investigate the Effect of 2 Single Doses (400 microg and 1200 microg) of Inhaled AZD3199 on QT/QTc Interval, Compared to Placebo, Using Moxifloxacin (Avelox) as a Positive Control, in Healthy Male Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2011

At a glance

  • Drugs AZD 3199; AZD 3199; Moxifloxacin
  • Indications Acute exacerbations of chronic bronchitis; Acute sinusitis; Asthma; Bacterial infections; Chronic obstructive pulmonary disease; Community-acquired pneumonia; Intra-abdominal infections; Pelvic inflammatory disorders; Respiratory tract infections; Skin and soft tissue infections; Tuberculosis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 23 Oct 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top